
Please try another search
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Michael G. Raab | 57 | 2009 | President, CEO & Director |
William C. Bertrand | 57 | 2015 | Independent Director |
Richard J. Rodgers | 55 | 2014 | Independent Director |
David M. Mott | 57 | 2009 | Independent Chairman of the Board |
Onaiza Cadoret-Manier | 60 | 2020 | Independent Director |
Muna Bhanji | 61 | 2021 | Independent Director |
Robert B. Bazemore | 56 | 2016 | Independent Director |
Merdad V. Parsey | 61 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review